Dr. Chen is AbVision’s founder and has served as a member of AbVision’s board of directors and as Chief Operating Officer since December 2018. He was also Founding Chief Scientific Officer until December 2018. Dr. Chen is an immunologist with expertise in antibody design for therapeutic use and new vaccine discovery for the treatment of human cancers and infectious disease. He completed his Ph.D. from Texas A&M University and has a track record of successful leadership roles in R&D, business development, and the marketing of therapeutic antibodies.
AbVision, Inc. (AVI) Biopharmaceutical company AbVision, Inc. (AVI) previously the Drug Discovery Group of BioVision Inc., is a privately held biopharmaceutical company headquartered in the San Francisco Bay Area. AVI’s most advanced drug discovery efforts aim to develop pipelines of cancer and infectious disease therapeutics that harness the natural power of the immune system to bring first-in-class and best-in-class drugs to the world.